Drugs / CHF 5074
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01258452 | Feb → Mar 2011 | Alzheimer disease | CERESPIR | Completed | No outcome recorded |
| Phase 1 | NCT01203384 | Sep → Dec 2010 | Alzheimer disease | CERESPIR | Completed | No outcome recorded |
| Phase 1 | NCT00954252 | Oct 2009 → May 2010 | Alzheimer disease | CERESPIR | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01723670 | Dec 2012 → Mar 2016 | Alzheimer disease | CERESPIR | Withdrawn | No outcome recorded |
| Phase 2 | NCT01602393 | May 2012 → Oct 2013 | Alzheimer disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01421056 | Jul 2011 → Nov 2012 | Alzheimer disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01303744 | Mar 2011 → Apr 2012 | Alzheimer disease | CERESPIR | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF 5074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01723670 ↗ |
| Route | Oral | “1x, oral capsule, single dose” NCT00954252 ↗ |